Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04811027
Title Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immutep S.A.S.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | DEU | BEL


No variant requirements are available.